Currently, Ms. Meda is Chief Business Officer at IncellDx, Inc. in Menlo Park CA, a cellular multiplex molecular diagnostic company focused in the areas of infectious disease and oncology with a particular emphasis on companion diagnostics partnerships with pharmaceutical companies. Chris has 30 years of leadership in the diagnostic and pharmaceutical industries. Her management responsibilities have included the creation of strategic business direction and plans, operations and commercialization of more than 30 products for various disease areas at Hoffman-LaRoche, Bio-Rad Laboratories, Diagnostics Products Corporation (now Siemens), Meridian Diagnostics and Schering AG pharmaceuticals. Chris is also Chair, of Women in BIO- San Francisco Chapter, an organization of professionals committed to promoting careers, leadership, and entrepreneurship of women in the life sciences; and, a Board Director for Claremont BioSolutions, a company providing laboratories with diagnostics and devices for molecular diagnostics and bioscience research. Through June, 2012, Ms. Meda was President of Response Genetics (RGI), a personalized medicine company that has developed PCR-based genetics tests for lung, colon, gastric and melanoma cancers which help medical oncologists with therapeutic treatment decisions for patients with these cancer types. Prior to RGI, she was CEO, President at Arcxis Biotechnologies a venture backed start-up with a focus on molecular diagnostic extraction devices and reagents. Arcxis was sold to Fluidigm in September, 2010. Prior to Arcxis, Chris was at Diamics, Inc a start-up with focus on a cervical cancer medical device. Diamics was sold to Inverness Medical Innovations (now Alere) in July, 2007. Prior to Diamics, Chris was Vice President at Hoffman-LaRoche, Roche Molecular Diagnostics Division for the Global Women’s Health Portfolio and subsequently became Vice President of Business Development. Her leadership role and portfolio duties included strategic planning for the portfolio, oversight of research and development and the commercialization of PCR-based diagnostics for Human Papillomavirus, Chlamydia, Herpes Simplex Virus and Group B Streptococcus. Her business development role was focused on companion diagnostics where she completed agreements between Roche Molecular Diagnostics and four pharmaceutical companies.